Pharma & Biotech - Page 17

Gilead Sciences has reached a significant commercial milestone, with its HIV prevention franchise surpassing $1 billion in quarterly sales for the very first time. The breakthrough was driven by strong performance from

Novo Nordisk’s oral Wegovy treatment continues to post impressive results in 2026, sustaining momentum as the company eyes broader international expansion beyond the United States. Chief Executive Mike Doustdar struck a confident

Alcon (ALC) has released findings from a new survey highlighting a significant disconnect between parental awareness of vision health and actual eye examination rates among teenagers. The survey, conducted by Wakefield Research

Galderma Laboratories has landed a significant blow against Sanofi in an ongoing multi-case advertising dispute over their rival eczema treatments. The BBB National Programs’ National Advertising Division ruled that Sanofi must change

Novo Nordisk has appointed Omnicom as its agency of record for US media buying, bringing an end to a six-year partnership with WPP’s Wavemaker. Omnicom will take over management of Novo Nordisk’s

AbbVie (ABBV) has reclaimed the number one position in pharmaceutical TV advertising after rival Johnson & Johnson (JNJ) briefly overtook it in June’s rankings. Skyrizi’s return to the top was driven by

The US Food and Drug Administration is launching a formal assessment of small dispensers’ ability to conduct interoperable, package-level product tracing under the Drug Supply Chain Security Act. The assessment targets pharmacies

Injected weight loss treatments continue to dominate physician preferences, with Eli Lilly’s (LLY) Zepbound leading the field despite a wave of new oral obesity medications arriving on the market. A Spherix Global

Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist 2 mg/1 mL due to a label mix-up. The recall centres on

Takeda Pharmaceutical has secured a significant regulatory milestone after its first-in-class orexin treatment received approval from the US Food and Drug Administration for narcolepsy. The approval marks a major breakthrough in narcolepsy